Testicular Lymphoma: Symptoms, Diagnosis, Prognosis, and Treatment

This entry looks at testicular lymphoma, or non-Hodgkin's lymphoma of the testis. 'Lymphoma' is an umbrella term that loosely refers to several dozen independent categorical types and subtypes of cancers of the lymphatic system; testicular lymphoma is one of those subtypes.

The disease is called primary testicular lymphoma (PTL) if it is found to originate in the testis. It is (less commonly) called secondary testicular lymphoma if the disease originates elsewhere in the body and has spread to the testis. This entry will chiefly address PTL.

What is Testicular Lymphoma?

Testicular lymphoma is a rare extranodal subtype of non-Hodgkin's lymphoma affecting the male testicles and is often pathologically diagnosed as an extranodal diffuse large B-cell lymphoma (DLBCL) of the testis. It is a rare cancer of the testis, amounting to less than ten percent of such cancers. The disease tends to have an aggressive clinical course, It is most often diagnosed in elderly men; however, an exception is in younger, male HIV positive patients, in whom PTL has a comparatively high incidence.

Symptoms and Diagnosis of Testicular Lymphoma

Most commonly, testicular lymphoma presents as a painless unilateral (one-sided) mass on the testis, although in about one-fifth of the cases, it is bilateral (affecting both testis). Self-testicular exams properly carried out can contribute to early detection.

Diagnosing testicular lymphoma will almost invariably require an orchidectomy (also spelled orchiectomy), which is the surgical removal of a testis (a procedure which keeps the scrotum and penis otherwise intact).

Prognosis and Treatment of Testicular Lymphoma

Treatment of testicular lymphoma generally involves some form of doxorubicin-based, systemic combination chemotherapy, such as R-CHOP. Another treatment is involved-field radiotherapy to the testis. In some cases, patients may receive both chemotherapy and radiation. The earlier the stage of the disease, the higher the success rate of treatment, although in the case of testicular lymphoma it appears that there is even a success rate difference between early stage disease (stage I and stage II).

When testicular lymphoma recurs following treatment, common sites include the central nervous system (CNS). For this reason, CNS prophylaxis (preventive medicine) could be necessary, in which case patients might receive intrathecal chemotherapy involving methotrexate, cytarabine and dexametasone.

Prognosis for most patients with testicular lymphoma is good, especially those diagnosed and treated for early-stage disease. However, later-stage disease is more difficult to treat and prognosis in these cases is considered rather poor.

Sources

Photo: Pexels

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap